All News

RheumNow Podcast square

Methotrexate Safety Tips (7.31.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
gout,podagra,MTP

Four Decades of Gout Management

Jack Cush, MD

During this month-long campaign on Gout, we have documented many significant changes in our approach to gout, as well as many unmet needs and deficiencies that merit our continued, primary attention.  We are all familiar with the famous 1905 quote, “Those who cannot remember the past are

Read Article
FDA.Safety.jpg

New Avacopan Analysis Sent to FDA

MedPage Today

After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January.

Read Article
pediatric.kid_.jpg

$2 Million in Research Grants for Juvenile Arthritis

Jack Cush, MD

July is Juvenile Arthritis Awareness Month, and while many people think of arthritis as a disease of aging, nearly 300,000 children in the U.S. are living with a rheumatic disease.

Read Article
dna

Genetic Risk Loci in Fibromyalgia

Jack Cush, MD

Researchers examined genetic data drawn from 11 different worldwide cohorts, that included from more than 2.5 million adults, of which 55,000 had been diagnosed with fibromyalgia. They identified DNA sequence variants in 26 regions of the genome that affect the risk of developing fibromyalgia. Many of the genes implicated in these regions are involved in brain and nerve function. This is the largest fibromyalgia GWAS to date.

Read Article
gout.tophi_.jpg

Uricase-Targeted Therapies in Gout

Jack Cush, MD

In most mammals, uricase catalyzes the oxidation of uric acid to allantoin, a highly soluble compound easily excreted by the kidneys. But humans lack functional uricase, leaving xanthine oxidase inhibitors (allopurinol/febuxostat) as first-line urate-lowering therapy (ULT). Uricase-based biologics are reserved for uncontrolled/refractory gout patients with gouty flares, active synovitis, and/or non-resolving tophi despite optimized oral ULT.

Read Article
Sausage062.jpg

The Wider Implications of Dactylitis

Jack Cush, MD

Dactylitis, AKA the "sausage digit", is a hallmark of psoriatic arthritis (PsA), but as Possemato and colleagues point out, it is fundamentally a clinical sign, and not a diagnosis. This review article discusses the wider implications of dactylitis in rheumatology and medicine underscores the diagnostic and prognostic significance of this manifestation.

Read Article
RheumNow Podcast square

Chikungunya Club Meeting (7.24.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.

Read Article
Calcium Pyrophosphate Deposition Dz new terminology from 2026 G-CAN consensus. Preferred: - acute CPP crystal arthritis - Chronic CPP crystal arthritis - Chronic CPP crystal arthritis - OA w/ CPP - Chondrocalcinosis (xray) * Pseudogout is obsolete https://t.co/bsztXz9UDs https://t.co/GOey5YmKif

Links:

Dr. John Cush RheumNow ( View Tweet)
Social Media (SM) for Health Information by US (sample 7278 adults) - SM use reported by 88% (representing ~ 228 million). ~22% adults made health decisions based on SM, despite almost 78% reporting distrust of SM. Lower SM use in older, rural, less educated. https://t.co/uYYzBvckFu
Dr. John Cush RheumNow ( View Tweet)
The Wider Implications of Dactylitis Dactylitis, AKA the "sausage digit", is a hallmark of psoriatic arthritis (PsA), but as Possemato and colleagues point out, it is fundamentally a clinical sign, and not a diagnosis. https://t.co/HRaIvMHMSV https://t.co/XOcHbFVMsS

Links:

Dr. John Cush RheumNow ( View Tweet)
Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - the 1st therapy approved for the most common form of vitiligo. Based on positive results from the Phase 3 Viti-Up trials https://t.co/MMv5LjZclQ https://t.co/zN41GC5T15

Links:

Dr. John Cush RheumNow ( View Tweet)
Upgrading & Maximizing the Classics Panelists: Dr. Angelo Gaffo Dr. Lisa Stamp Dr. Michael Pillinger Dr. Ted Mikuls Dr. Jack Cush (moderator) https://t.co/gO4CQD2f19 https://t.co/ESSLL0iK8F

Links:

Dr. John Cush RheumNow ( View Tweet)
Swimming Reduces Disability from Low Back Pain Swimming is commonly recommended for patients with chronic low back pain. Yet, there is little trial data investigating swimming. An Australian study has shown for the first time that a program of swimming can be clinically https://t.co/OfxsvRjyJg
Dr. John Cush RheumNow ( View Tweet)
3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo https://t.co/9YAmPqW44z

Links:

Dr. John Cush RheumNow ( View Tweet)
Calcium Pyrophosphate Deposition Dz new terminology from 2026 G-CAN consensus. Preferred: - acute CPP crystal arthritis - Chronic CPP crystal arthritis - Chronic CPP crystal arthritis - OA w/ CPP - Chondrocalcinosis (xray) * Pseudogout is obsolete https://t.co/L95N2ObHr3 https://t.co/ST7RkJa8BR

Links:

Dr. John Cush RheumNow ( View Tweet)
An AI model trained from routine electronic health record data of 3.7 million individuals predicted cancer 1 year before clinical onset, no less promoted accuracy in detection, staging, treatment response, and prognosis https://t.co/ORrpJ2vIcR https://t.co/ymJWRAYOSw

Links:

Eric Topol EricTopol ( View Tweet)
Primary biliary cholangitis is a chronic cholestatic disease characterized by autoimmune-mediated destruction of bile ducts, leading to fibrosis, cirrhosis, & liver failure. Ursodeoxycholic acid is 1st line Rx. New Rx include elafibranor & seladelpar (activates peroxisome https://t.co/tKloXvJYek
Dr. John Cush RheumNow ( View Tweet)
Expert Perspective on Calcium Pyrophosphate Deposition Disease A current perspective article by Dr. Sara Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments. https://t.co/zxJ9aQweNl
Dr. John Cush RheumNow ( View Tweet)
Nerandomilast (Jascayd) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The drug was approved for IPF & PPF by the FDA for US use in late 2025 https://t.co/scOuVb3aYy https://t.co/EcmpRhyWgu

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×